LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedRC
RA Capital Management
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.
Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.
Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.
Sources
- Rounds participated in
- 9
- Confirmed lead rounds
- — 9 roles undisclosed
- New companies
- 9 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.3B 9 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
9 in this selectionCelea Therapeutics
Develops treatments for serious respiratory diseases
$180MGrowth
Role not disclosedOllin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedNorthLinks Bio
Develops broad-spectrum antiviral prophylactic therapies for respiratory infections
$34MUndisclosed
Role not disclosedContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosedSecretome Therapeutics
Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy
$30MSeries A
Role not disclosedCellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedNexCure
Provides CAR-T and other advanced treatment delivery in community outpatient settings
$19MSeries A
Role not disclosedSlate Medicines
Advancing next-generation therapeutics for migraine and other headache disorders
$130MSeries A
Role not disclosed